Induction	O
of	O
the	O
pro-myelocytic	B-DNA
leukaemia	I-DNA
gene	I-DNA
by	O
type	B-protein
I	I-protein
and	I-protein
type	I-protein
II	I-protein
interferons	I-protein
.	O

The	O
physiological	O
role	O
of	O
the	O
pro-myelocytic	B-protein
leukaemia	I-protein
(	I-protein
PML	I-protein
)	I-protein
gene	I-protein
product	I-protein
is	O
poorly	O
defined	O
.	O

Among	O
other	O
functions	O
,	O
PML	B-DNA
is	O
involved	O
in	O
haematopoietic	O
differentiation	O
and	O
in	O
control	O
of	O
cell	O
growth	O
and	O
tumorigenesis	O
.	O

We	O
investigated	O
the	O
regulation	O
of	O
human	O
PML	B-DNA
expression	O
by	O
interferons	B-protein
(	O
IFNs	B-protein
)	O
and	O
IL-1	B-protein
in	O
various	O
human	B-cell_line
haematopoietic	I-cell_line
lines	I-cell_line
(	O
U937	B-cell_line
,	O
THP1	B-cell_line
,	O
HL60	B-cell_line
,	O
NB4	B-cell_line
)	O
,	O
in	O
human	B-cell_type
diploid	I-cell_type
fibroblasts	I-cell_type
and	O
in	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
leukocytes	I-cell_type
.	O

Cytokine-induced	O
modulation	O
of	O
PML	B-DNA
expression	O
was	O
assessed	O
by	O
Northern	O
blot	O
analyses	O
,	O
flow	O
cytometry	O
studies	O
and	O
in	O
situ	O
immunolabelling	O
.	O

Our	O
data	O
show	O
that	O
IFNs	B-protein
and	O
IL-1	B-protein
upregulate	O
PML	O
transcript	O
and	O
protein	O
expression	O
in	O
a	O
time	O
and	O
dose-dependent	O
manner	O
.	O

In	O
situ	O
immunolabelling	O
revealed	O
that	O
upregulation	O
of	O
protein	O
expression	O
by	O
IFN-alpha	B-protein
is	O
a	O
consequence	O
of	O
a	O
marked	O
increase	O
in	O
both	O
the	O
number	O
and	O
the	O
intensity	O
of	O
the	O
staining	O
of	O
so-called	O
PML	B-protein
nuclear	I-protein
bodies	I-protein
.	O

Our	O
data	O
suggest	O
that	O
stimulation	O
of	O
PML	B-DNA
expression	O
by	O
interferons	B-protein
and	O
IL-1	B-protein
may	O
account	O
for	O
upregulation	O
of	O
PML	B-protein
proteins	I-protein
observed	O
in	O
inflammatory	O
tissues	O
and	O
in	O
proliferative	O
states	O
.	O

Research	NULL
Paper	NULL
Tar	NULL
physiological	NULL
role	NULL
of	NULL
the	NULL
pro-myelocytic	NULL
leukaemia	NULL
(	NULL
PML	NULL
)	NULL
gene	NULL
product	NULL
is	NULL
poorly	NULL
defined	NULL
.	NULL

Among	NULL
other	NULL
functions	NULL
,	NULL
PML	NULL
is	NULL
involved	NULL
in	NULL
haematopoietic	NULL
differentiation	NULL
and	NULL
in	NULL
control	NULL
of	NULL
cell	NULL
growth	NULL
and	NULL
tumorigenesis	NULL
.	NULL

We	NULL
investigated	NULL
the	NULL
regulation	NULL
of	NULL
human	NULL
PML	NULL
expression	NULL
by	NULL
interferons	NULL
(	NULL
IFNs	NULL
)	NULL
and	NULL
IL-1	NULL
in	NULL
various	NULL
human	NULL
haematopoietic	NULL
lines	NULL
(	NULL
U937	NULL
,	NULL
THP1	NULL
,	NULL
HIL60	NULL
,	NULL
NB4	NULL
)	NULL
,	NULL
in	NULL
human	NULL
diploid	NULL
fibroblasts	NULL
and	NULL
in	NULL
human	NULL
peripheral	NULL
blood	NULL
leukocytes	NULL
.	NULL

Cytokine-induced	NULL
modulation	NULL
of	NULL
PML	NULL
expression	NULL
was	NULL
assessed	NULL
by	NULL
Northern	NULL
blot	NULL
analyses	NULL
,	NULL
flow	NULL
cytometry	NULL
studies	NULL
and	NULL
in	NULL
situ	NULL
immunolabelling	NULL
.	NULL

Our	NULL
data	NULL
show	NULL
that	NULL
IFNs	NULL
and	NULL
IL-1	NULL
upregulate	NULL
PML	NULL
transcript	NULL
and	NULL
protein	NULL
expression	NULL
in	NULL
a	NULL
time	NULL
and	NULL
dose-dependent	NULL
manner	NULL
.	NULL

In	NULL
situ	NULL
immunolabelling	NULL
revealed	NULL
that	NULL
upregulation	NULL
of	NULL
protein	NULL
expression	NULL
by	NULL
IFN-	NULL
@	NULL
is	NULL
a	NULL
consequence	NULL
of	NULL
a	NULL
marked	NULL
increase	NULL
in	NULL
both	NULL
the	NULL
number	NULL
and	NULL
the	NULL
intensity	NULL
of	NULL
the	NULL
staining	NULL
of	NULL
so-called	NULL
PML	NULL
nuclear	NULL
bodies	NULL
.	NULL

Our	NULL
data	NULL
suggest	NULL
that	NULL
stimulation	NULL
of	NULL
PML	NULL
expression	NULL
by	NULL
interferons	NULL
and	NULL
IL-1	NULL
may	NULL
account	NULL
for	NULL
upregulation	NULL
of	NULL
PML	NULL
proteins	NULL
observed	NULL
in	NULL
inflammatory	NULL
tissues	NULL
and	NULL
in	NULL
proliferative	NULL
states	NULL
.	NULL

Key	NULL
words	NULL
:	NULL
PML	NULL
,	NULL
Interferons	NULL
,	NULL
IL-1	NULL
Mediators	NULL
of	NULL
Inflammation	NULL
,	NULL
7	NULL
,	NULL
319-325	NULL
(	NULL
1998	NULL
)	NULL
Induction	NULL
of	NULL
the	NULL
pro-myelocytic	NULL
leukaemia	NULL
gene	NULL
by	NULL
type	NULL
I	NULL
and	NULL
type	NULL
II	NULL
interferons	NULL
M.	NULL
Heuser	NULL
,	NULL
``	NULL
H.	NULL
van	NULL
der	NULL
Kuip	NULL
,	NULL
'	NULL
B.	NULL
Falini	NULL
,	NULL
*	NULL
C.	NULL
Peschel	NULL
,	NULL
'	NULL
C.	NULL
Huber	NULL
and	NULL
T.	NULL
Fischer	NULL
``	NULL
'lII	NULL
.	NULL

Medical	NULL
Department	NULL
,	NULL
Johannes-Gutenberg-University	NULL
Mainz	NULL
,	NULL
Langenbeckstr	NULL
.	NULL

1	NULL
,	NULL
55131	NULL
Mainz	NULL
,	NULL
Germany	NULL
;	NULL
Istituto	NULL
Clinica	NULL
Medica	NULL
I	NULL
,	NULL
University	NULL
of	NULL
Perugia	NULL
,	NULL
Policlinico	NULL
,	NULL
Monteluce	NULL
,	NULL
06100	NULL
Perugia	NULL
,	NULL
Italy	NULL
CACorresponding	NULL
Author	NULL
Tel	NULL
:	NULL
(	NULL
+49	NULL
)	NULL
6131	NULL
176	NULL
544	NULL
Fax	NULL
:	NULL
(	NULL
+49	NULL
)	NULL
6131	NULL
176	NULL
678	NULL
Email	NULL
:	NULL
tfischer	NULL
@	NULL
3-med.klinik.uni-mainz.de	NULL
Introduction	NULL
The	NULL
PML	NULL
(	NULL
promyelocytic	NULL
leukaemia	NULL
)	NULL
gene	NULL
was	NULL
identified	NULL
originally	NULL
as	NULL
a	NULL
fusion	NULL
partner	NULL
of	NULL
the	NULL
RARQG	NULL
gene	NULL
in	NULL
the	NULL
chromosomal	NULL
translocation	NULL
t	NULL
(	NULL
15	NULL
;	NULL
17	NULL
)	NULL
specific	NULL
for	NULL
acute	NULL
promyelocytic	NULL
leukaemia	NULL
(	NULL
APL	NULL
)	NULL
..~4	NULL
Several	NULL
PML-cDNAs	NULL
have	NULL
been	NULL
isolated	NULL
,	NULL
resulting	NULL
from	NULL
alternative	NULL
RNA	NULL
splicing	NULL
in	NULL
the	NULL
3	NULL
``	NULL
coding	NULL
region	NULL
of	NULL
a	NULL
single	NULL
gene.5	NULL
The	NULL
encoded	NULL
proteins	NULL
have	NULL
a	NULL
predicted	NULL
molecular	NULL
weight	NULL
ranging	NULL
from	NULL
47	NULL
to	NULL
98	NULL
kDa	NULL
.	NULL

PML	NULL
proteins	NULL
belong	NULL
to	NULL
a	NULL
heterogeneous	NULL
family	NULL
of	NULL
DNA-binding	NULL
proteins	NULL
characterized	NULL
by	NULL
the	NULL
C	NULL
;	NULL
HC	NULL
,	NULL
zinc	NULL
binding	NULL
ring	NULL
finger	NULL
.	NULL

PML	NULL
protein	NULL
expression	NULL
features	NULL
a	NULL
typical	NULL
speckled	NULL
nuclear	NULL
pattern	NULL
which	NULL
is	NULL
the	NULL
consequence	NULL
of	NULL
the	NULL
localization	NULL
of	NULL
the	NULL
protein	NULL
in	NULL
nuclear	NULL
compartments	NULL
named	NULL
nuclear	NULL
bodies	NULL
.	NULL
``	NULL

The	NULL
function	NULL
of	NULL
the	NULL
PML	NULL
nuclear	NULL
bodies	NULL
is	NULL
still	NULL
unknown	NULL
.	NULL

Recently	NULL
it	NULL
has	NULL
been	NULL
shown	NULL
that	NULL
PML	NULL
participates	NULL
in	NULL
regulation	NULL
of	NULL
haematopoietic	NULL
differentiation	NULL
and	NULL
in	NULL
control	NULL
of	NULL
cell	NULL
grow	NULL
th	NULL
and	NULL
turnorigmlesis.6	NULL
In	NULL
addition	NULL
,	NULL
there	NULL
is	NULL
evidence	NULL
that	NULL
PML	NULL
protein	NULL
is	NULL
aberrantly	NULL
expressed	NULL
in	NULL
a	NULL
variety	NULL
of	NULL
pathological	NULL
conditions	NULL
including	NULL
malig-nancies	NULL
.	NULL
``	NULL

The	NULL
level	NULL
of	NULL
PML	NULL
expression	NULL
is	NULL
upregulated	NULL
in	NULL
inflammatory	NULL
tissues	NULL
and	NULL
in	NULL
benign	NULL
or	NULL
malignant	NULL
prolife	NULL
rative	NULL
states	NULL
.	NULL
``	NULL

''	NULL
Cytokines	NULL
,	NULL
especially	NULL
interferons	NULL
(	NULL
IFNs	NULL
)	NULL
,	NULL
are	NULL
likely	NULL
to	NULL
represent	NULL
some	NULL
of	NULL
the	NULL
mediators	NULL
that	NULL
may	NULL
be	NULL
involved	NULL
in	NULL
overexpression	NULL
of	NULL
PML	NULL
under	NULL
these	NULL
Interferons	NULL
are	NULL
polypeptides	NULL
that	NULL
mediate	NULL
pleiotropic	NULL
effects	NULL
on	NULL
sensitive	NULL
cells	NULL
(	NULL
reviewed	NULL
in	NULL
Sen	NULL
and	NULL
hngyello	NULL
)	NULL
.	NULL

Major	NULL
activities	NULL
of	NULL
IFNs	NULL
include	NULL
immunomodulating	NULL
activ-	NULL
0962-9351/98/050319-07	NULL
$	NULL
9.00	NULL
Â©	NULL
1998	NULL
Carfax	NULL
Publishing	NULL
Ltd	NULL
circumstances	NULL
.	NULL

ities	NULL
,	NULL
antiviral	NULL
effects	NULL
and	NULL
inhibition	NULL
of	NULL
cellular	NULL
growth	NULL
.	NULL

Two	NULL
families	NULL
of	NULL
IFNs	NULL
can	NULL
be	NULL
distinguished	NULL
:	NULL
type	NULL
I	NULL
IFNs	NULL
(	NULL
IFN	NULL
@	NULL
/B	NULL
and	NULL
IFN	NULL
)	NULL
and	NULL
type	NULL
II	NULL
IFN	NULL
(	NULL
y	NULL
)	NULL
.	NULL

Type	NULL
I	NULL
IFNs	NULL
are	NULL
encoded	NULL
by	NULL
a	NULL
family	NULL
of	NULL
over	NULL
20	NULL
genes	NULL
,	NULL
whereas	NULL
type	NULL
II	NULL
IFN	NULL
is	NULL
structurally	NULL
unrelated	NULL
and	NULL
encoded	NULL
by	NULL
a	NULL
single	NULL
gene.10An	NULL
important	NULL
function	NULL
of	NULL
IFNs	NULL
is	NULL
regulation	NULL
of	NULL
cellular	NULL
growth	NULL
of	NULL
normal	NULL
and	NULL
malignant	NULL
cells	NULL
.	NULL

The	NULL
molecular	NULL
mechanisms	NULL
involved	NULL
in	NULL
grow	NULL
th	NULL
inhibition	NULL
are	NULL
pootly	NULL
understood	NULL
.	NULL

Here	NULL
,	NULL
we	NULL
investigated	NULL
modulation	NULL
of	NULL
PML	NULL
expression	NULL
by	NULL
interferons	NULL
,	NULL
TNF	NULL
and	NULL
IL-1	NULL
.	NULL

We	NULL
present	NULL
evidence	NULL
that	NULL
PML	NULL
gene	NULL
expression	NULL
is	NULL
enhanced	NULL
by	NULL
type	NULL
I	NULL
and	NULL
type	NULL
II	NULL
interferons	NULL
and	NULL
by	NULL
IL-1	NULL
.	NULL

We	NULL
analysed	NULL
cytokine	NULL
induced	NULL
up-regulation	NULL
of	NULL
PML	NULL
transcript	NULL
and	NULL
protein	NULL
expression	NULL
in	NULL
human	NULL
haematopoietic	NULL
cell	NULL
lines	NULL
,	NULL
in	NULL
human	NULL
diploid	NULL
fibroblasts	NULL
and	NULL
in	NULL
human	NULL
peripheral	NULL
blood	NULL
leukocytes	NULL
.	NULL

Modulation	NULL
of	NULL
PML	NULL
protein	NULL
expression	NULL
by	NULL
IFN	NULL
and	NULL
IL-1	NULL
was	NULL
assessed	NULL
with	NULL
immunofluorescence	NULL
flow	NULL
cytometry	NULL
.	NULL

Immunofluorescence	NULL
fr	NULL
site	NULL
analysis	NULL
of	NULL
PML	NULL
nuclear	NULL
bodies	NULL
revealed	NULL
that	NULL
IFN	NULL
treatment	NULL
resulted	NULL
in	NULL
up-regulation	NULL
of	NULL
both	NULL
the	NULL
intensity	NULL
and	NULL
the	NULL
number	NULL
of	NULL
these	NULL
nuclear	NULL
structures	NULL
.	NULL

Materials	NULL
and	NULL
methods	NULL
Cell	NULL
culture	NULL
and	NULL
materials	NULL
HL60	NULL
,	NULL
NB4	NULL
,	NULL
U937	NULL
and	NULL
THP1	NULL
cells	NULL
were	NULL
obtained	NULL
from	NULL
the	NULL
American	NULL
Type	NULL
Culture	NULL
Collection	NULL
(	NULL
Rockville	NULL
,	NULL
MD	NULL
,	NULL
USA	NULL
)	NULL
.	NULL

Peripheral	NULL
blood	NULL
mononuclear	NULL
cells	NULL
(	NULL
PBMNC	NULL
)	NULL
319	NULL
M.	NULL
Heuser	NULL
et	NULL
al	NULL
.	NULL

were	NULL
isolated	NULL
from	NULL
heparinized	NULL
venous	NULL
blood	NULL
from	NULL
normal	NULL
donors	NULL
by	NULL
FiollHypaque	NULL
(	NULL
Iymphoprep	NULL
,	NULL
Nye-gaard	NULL
,	NULL
Norway	NULL
)	NULL
density	NULL
separation	NULL
as	NULL
described	NULL
.	NULL
``	NULL

Human	NULL
diploid	NULL
foreskin	NULL
fibroblasts	NULL
were	NULL
obtained	NULL
from	NULL
the	NULL
Department	NULL
of	NULL
Dermatology	NULL
,	NULL
University	NULL
of	NULL
Mainz	NULL
,	NULL
Germany	NULL
.	NULL

All	NULL
cells	NULL
were	NULL
grow	NULL
n	NULL
in	NULL
RPMI	NULL
1640	NULL
(	NULL
Seromed	NULL
,	NULL
Munich	NULL
,	NULL
Germany	NULL
)	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
fetal	NULL
calf	NULL
serum	NULL
(	NULL
PAA	NULL
,	NULL
Colbe	NULL
,	NULL
Germany	NULL
)	NULL
,	NULL
penicillin	NULL
50	NULL
IU/ml	NULL
(	NULL
Serva	NULL
,	NULL
Heidelberg	NULL
,	NULL
Germany	NULL
)	NULL
,	NULL
streptomycin	NULL
501U/ml	NULL
(	NULL
Serva	NULL
)	NULL
,	NULL
sodiumpytuvate	NULL
1	NULL
nmol/l	NULL
,	NULL
Lglutamine	NULL
-	NULL
2	NULL
mmol/l	NULL
_	NULL
(	NULL
Seromed	NULL
)	NULL
,	NULL
-	NULL
Lasparagine	NULL
20	NULL
ug/ml	NULL
(	NULL
Boehringer	NULL
,	NULL
Mannheim	NULL
,	NULL
Germany	NULL
)	NULL
,	NULL
2-mer-captoethanol	NULL
0.05	NULL
mmol/l	NULL
,	NULL
HEPES	NULL
10	NULL
mmol/l	NULL
,	NULL
and	NULL
nonessential	NULL
aminoacids	NULL
(	NULL
Seromed	NULL
)	NULL
at	NULL
37Â°C	NULL
and	NULL
5	NULL
%	NULL
CO	NULL
;	NULL
as	NULL
described	NULL
.	NULL
``	NULL

rh-IFNG2b	NULL
with	NULL
a	NULL
specific	NULL
activity	NULL
of	NULL
1.8	NULL
X	NULL
10Â°	NULL
IU/	NULL
mg	NULL
was	NULL
obtained	NULL
from	NULL
Essex	NULL
Pharma	NULL
(	NULL
Munich	NULL
,	NULL
Germany	NULL
)	NULL
.	NULL

h-IFN-Y	NULL
was	NULL
purchased	NULL
from	NULL
Thomae	NULL
(	NULL
Bibe	NULL
rach	NULL
,	NULL
Germany	NULL
)	NULL
.	NULL

thIL-1G	NULL
was	NULL
kindly	NULL
provided	NULL
by	NULL
Hoffmann	NULL
La	NULL
Roche	NULL
(	NULL
Nutley	NULL
,	NULL
NJ	NULL
)	NULL
,	NULL
th-TNF	NULL
(	NULL
6.6	NULL
X	NULL
10Â°	NULL
IU/mg	NULL
)	NULL
by	NULL
Knoll	NULL
AG	NULL
(	NULL
Ludwigshafen	NULL
,	NULL
Germany	NULL
)	NULL
and	NULL
rhIJFN-LB	NULL
(	NULL
3	NULL
X	NULL
10Â°	NULL
IU/mg	NULL
)	NULL
by	NULL
Bioferon	NULL
(	NULL
Laupheim	NULL
,	NULL
Germany	NULL
)	NULL
.	NULL

Northern	NULL
blot	NULL
analysis	NULL
Total	NULL
RNA	NULL
was	NULL
isolated	NULL
by	NULL
the	NULL
method	NULL
of	NULL
Chomezyn-ski	NULL
and	NULL
Sacchi	NULL
``	NULL
and	NULL
Northern	NULL
blot	NULL
analysis	NULL
was	NULL
performed	NULL
essentially	NULL
as	NULL
described	NULL
.	NULL
``	NULL

RNA	NULL
(	NULL
20	NULL
ug	NULL
)	NULL
was	NULL
subjected	NULL
to	NULL
electrophoresis	NULL
on	NULL
a	NULL
1	NULL
%	NULL
formaldehyde	NULL
agarose	NULL
gel	NULL
and	NULL
transferred	NULL
to	NULL
nylon	NULL
membranes	NULL
(	NULL
Hybond	NULL
N	NULL
,	NULL
Amersham	NULL
Buchletr	NULL
,	NULL
Braunschweig	NULL
,	NULL
Germany	NULL
)	NULL
.	NULL

All	NULL
hybridizations	NULL
were	NULL
carried	NULL
out	NULL
at	NULL
65Â°C	NULL
for	NULL
16	NULL
h	NULL
in	NULL
a	NULL
solution	NULL
containing	NULL
1	NULL
%	NULL
BSA	NULL
,	NULL
7	NULL
%	NULL
SDS	NULL
,	NULL
1	NULL
mM	NULL
EDTA	NULL
,	NULL
and	NULL
0.5	NULL
M	NULL
sodium	NULL
phosphate	NULL
buffer	NULL
(	NULL
pH	NULL
7.2	NULL
)	NULL
.	NULL

Filters	NULL
were	NULL
hybridized	NULL
with	NULL
PML	NULL
cDNA	NULL
insert	NULL
radi-olabelled	NULL
by	NULL
the	NULL
random	NULL
priming	NULL
method	NULL
.	NULL

A	NULL
partial	NULL
cDNA	NULL
probe	NULL
for	NULL
PML	NULL
was	NULL
synthesized	NULL
by	NULL
RFPCR	NULL
from	NULL
total	NULL
RNA	NULL
of	NULL
THP1	NULL
cells	NULL
using	NULL
primers	NULL
S1	NULL
:	NULL
5	NULL
and	NULL
AS1	NULL
:	NULL
5	NULL
corre	NULL
sponding	NULL
to	NULL
nucleotides	NULL
525-544	NULL
and	NULL
715-734	NULL
,	NULL
respectively	NULL
of	NULL
the	NULL
published	NULL
sequence.13	NULL
This	NULL
part	NULL
of	NULL
the	NULL
PML	NULL
sequence	NULL
is	NULL
100	NULL
%	NULL
homologous	NULL
for	NULL
all	NULL
PML	NULL
genes	NULL
.	NULL

The	NULL
synthesized	NULL
cDNA	NULL
was	NULL
controlled	NULL
by	NULL
DNA-sequencing	NULL
and	NULL
was	NULL
subcloned	NULL
into	NULL
pCRITM	NULL
II	NULL
using	NULL
a	NULL
commercial	NULL
cloning	NULL
kit	NULL
(	NULL
Invitrogen	NULL
,	NULL
Leek	NULL
,	NULL
Netherlands	NULL
)	NULL
.	NULL

For	NULL
quantitative	NULL
analysis	NULL
of	NULL
mRNA	NULL
levels	NULL
densitometric	NULL
scanning	NULL
of	NULL
autoradiographs	NULL
was	NULL
applied	NULL
by	NULL
using	NULL
the	NULL
QuantiscanÂ®	NULL
program	NULL
.	NULL

PMLspecific	NULL
transcript	NULL
levels	NULL
were	NULL
normalized	NULL
to	NULL
B-actin	NULL
mRNA	NULL
expression	NULL
.	NULL

Immunofluorescence	NULL
analysis	NULL
Quantitative	NULL
immunofluorescence	NULL
studies	NULL
of	NULL
PML	NULL
expression	NULL
were	NULL
performed	NULL
by	NULL
flow	NULL
cytometry	NULL
(	NULL
EPICS	NULL
,	NULL
Coulter	NULL
,	NULL
Germany	NULL
)	NULL
as	NULL
described	NULL
``	NULL
by	NULL
using	NULL
saturating	NULL
concentrations	NULL
of	NULL
a	NULL
PML	NULL
specific	NULL
mAb	NULL
.	NULL
``	NULL

Normal	NULL
mouse	NULL
IgG	NULL
(	NULL
2	NULL
ug/ml	NULL
)	NULL
(	NULL
Coulter	NULL
,	NULL
Krefeld	NULL
,	NULL
Ger	NULL
320	NULL
Mediators	NULL
of	NULL
Inflammation	NULL
-	NULL
Vol	NULL
7	NULL
-	NULL
1998	NULL
many	NULL
)	NULL
was	NULL
used	NULL
as	NULL
background	NULL
control	NULL
,	NULL
and	NULL
FITC-labelled	NULL
goatantimouse	NULL
IgG	NULL
(	NULL
Coulter	NULL
,	NULL
Krefeld	NULL
,	NULL
Germany	NULL
)	NULL
as	NULL
second	NULL
reagent	NULL
.	NULL

A	NULL
total	NULL
of	NULL
50000	NULL
cells	NULL
was	NULL
analysed	NULL
for	NULL
each	NULL
determination	NULL
and	NULL
specific	NULL
fluorescence	NULL
intensity	NULL
was	NULL
calculated	NULL
on	NULL
the	NULL
basis	NULL
of	NULL
background	NULL
fluorescence	NULL
with	NULL
control	NULL
antibodies	NULL
by	NULL
using	NULL
the	NULL
EPICS	NULL
program	NULL
.	NULL

Mean	NULL
specific	NULL
fluorescence	NULL
intensity	NULL
is	NULL
given	NULL
as	NULL
channel	NULL
number	NULL
on	NULL
a	NULL
log	NULL
scale	NULL
from	NULL
1	NULL
to	NULL
1024	NULL
or	NULL
in	NULL
percentage	NULL
of	NULL
the	NULL
respective	NULL
untreated	NULL
control	NULL
.	NULL

Indirect	NULL
immunofluorescence	NULL
microscopy	NULL
Cells	NULL
were	NULL
air	NULL
dryed	NULL
overnight	NULL
,	NULL
fixed	NULL
for	NULL
5	NULL
min	NULL
with	NULL
aceton	NULL
followed	NULL
by	NULL
incubation	NULL
w	NULL
ith	NULL
PG-M3	NULL
antibody14	NULL
as	NULL
undiluted	NULL
hybridoma	NULL
supernatant	NULL
or	NULL
with	NULL
normal	NULL
mouse	NULL
IgG	NULL
(	NULL
Coulter	NULL
,	NULL
Krefeld	NULL
,	NULL
Germany	NULL
)	NULL
at	NULL
a	NULL
concentration	NULL
of	NULL
2	NULL
ug/ml	NULL
for	NULL
5	NULL
min	NULL
.	NULL

Cells	NULL
were	NULL
then	NULL
washed	NULL
with	NULL
PBS	NULL
and	NULL
incubated	NULL
w	NULL
ith	NULL
a	NULL
FITC	NULL
labelled	NULL
goat-anti-antibody	NULL
(	NULL
Coulter	NULL
,	NULL
Krefeld	NULL
,	NULL
Germany	NULL
)	NULL
(	NULL
5	NULL
ug/ml	NULL
)	NULL
.	NULL

Cells	NULL
were	NULL
analysed	NULL
with	NULL
a	NULL
fluorescence	NULL
microscope	NULL
(	NULL
Orthoplan	NULL
,	NULL
Leitz	NULL
,	NULL
Wetzlar	NULL
,	NULL
Germany	NULL
)	NULL
.	NULL

mouse	NULL
Results	NULL
PML	NULL
mRNA	NULL
levels	NULL
are	NULL
upregulated	NULL
by	NULL
type	NULL
I	NULL
and	NULL
type	NULL
II	NULL
interferons	NULL
To	NULL
investigate	NULL
whether	NULL
IFN	NULL
affects	NULL
PML	NULL
gene	NULL
expression	NULL
,	NULL
we	NULL
performed	NULL
Northern	NULL
blot	NULL
analyses	NULL
of	NULL
total	NULL
cellular	NULL
RNA	NULL
extracted	NULL
from	NULL
various	NULL
haematopoietic	NULL
cell	NULL
lines	NULL
cultured	NULL
with	NULL
and	NULL
without	NULL
IFNs	NULL
.	NULL

In	NULL
all	NULL
cell	NULL
types	NULL
tested	NULL
including	NULL
the	NULL
myeloid	NULL
cell	NULL
lines	NULL
HL6O	NULL
and	NULL
THP1	NULL
,	NULL
human	NULL
diploid	NULL
fibroblasts	NULL
and	NULL
human	NULL
peripheral	NULL
blood	NULL
mononuclear	NULL
cells	NULL
a	NULL
marked	NULL
increase	NULL
in	NULL
the	NULL
three	NULL
major	NULL
PML	NULL
transcript	NULL
levels	NULL
was	NULL
observed	NULL
by	NULL
treatment	NULL
with	NULL
both	NULL
type	NULL
I	NULL
(	NULL
,	NULL
B	NULL
)	NULL
and	NULL
type	NULL
II	NULL
(	NULL
Y	NULL
)	NULL
interferons	NULL
(	NULL
Figs	NULL
1-4	NULL
)	NULL
.	NULL

Dose	NULL
response	NULL
experiments	NULL
<	NULL
<	NULL
6	NULL
6	NULL
<	NULL
0QÂ§Â®QÂ§Â®QbÂ°	NULL
Â°\Â°\\\	NULL
a	NULL
Â¢	NULL
_	NULL
Â«	NULL
C	NULL
w	NULL
C	NULL
â¬	NULL
QQQQQQQQQQQ	NULL
o	NULL
Â§	NULL
Â®	NULL
8	NULL
Â§	NULL
8	NULL
$	NULL
8	NULL
$	NULL
2	NULL
Z	NULL
Z	NULL
2	NULL
P	NULL
&	NULL
2	NULL
@	NULL
F	NULL
â¬	NULL
Â¢	NULL
Â¢	NULL
Â¢	NULL
A	NULL
$	NULL
}	NULL
-	NULL
28	NULL
S	NULL
PML	NULL
wit	NULL
t	NULL
-	NULL
18	NULL
S	NULL
B-actin	NULL
FIG	NULL
.	NULL

1	NULL
.	NULL

Induction	NULL
of	NULL
PML	NULL
mRNA	NULL
by	NULL
interferon	NULL
.	NULL

Northern	NULL
blot	NULL
analysis	NULL
of	NULL
PML-specific	NULL
mRNA	NULL
levels	NULL
from	NULL
IFN-treated	NULL
and	NULL
untreated	NULL
PBMNC	NULL
.	NULL

PBMNC	NULL
were	NULL
treated	NULL
with	NULL
the	NULL
indicated	NULL
dose	NULL
of	NULL
IFN-	NULL
Â«	NULL
,	NULL
IFN-B	NULL
,	NULL
TNF-	NULL
Â«	NULL
or	NULL
LPS	NULL
for	NULL
6h	NULL
.	NULL

Medium	NULL
treated	NULL
PBMNC	NULL
and	NULL
freshly	NULL
isolated	NULL
PBMNC	NULL
without	NULL
further	NULL
incubation	NULL
were	NULL
included	NULL
as	NULL
controls	NULL
.	NULL

Size	NULL
fractionated	NULL
total	NULL
cellular	NULL
RNA	NULL
(	NULL
20,49	NULL
per	NULL
lane	NULL
)	NULL
was	NULL
blotted	NULL
and	NULL
hybridized	NULL
to	NULL
the	NULL
indicated	NULL
Â°	NULL
``	NULL
P-labelled	NULL
cDNA	NULL
probes	NULL
.	NULL

For	NULL
quantitative	NULL
analysis	NULL
of	NULL
mRNA	NULL
levels	NULL
densitometric	NULL
scanning	NULL
of	NULL
autoradiographs	NULL
was	NULL
applied	NULL
as	NULL
described	NULL
in	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL

PML	NULL
gene	NULL
expression	NULL
is	NULL
upregulated	NULL
by	NULL
interferons	NULL
and	NULL
IL-1	NULL
PML	NULL
B-actin	NULL
FIG	NULL
.	NULL

2	NULL
.	NULL

Time-response	NULL
of	NULL
induction	NULL
of	NULL
PML	NULL
mRNA	NULL
by	NULL
IFN-	NULL
Â«	NULL
and	NULL
IFN-B	NULL
.	NULL

Northern	NULL
blot	NULL
analysis	NULL
of	NULL
PML-specific	NULL
mRNA	NULL
levels	NULL
from	NULL
IFN-treated	NULL
and	NULL
untreated	NULL
PBMNC	NULL
.	NULL

PBMNC	NULL
were	NULL
treated	NULL
with	NULL
the	NULL
indicated	NULL
dose	NULL
of	NULL
IFN-	NULL
Â«	NULL
and	NULL
IFN-B	NULL
for	NULL
the	NULL
indicated	NULL
time	NULL
.	NULL

Medium-treated	NULL
PBMNC	NULL
and	NULL
freshly	NULL
isolated	NULL
PBMNC	NULL
without	NULL
further	NULL
incubation	NULL
were	NULL
included	NULL
as	NULL
controls	NULL
.	NULL

Size	NULL
fractionated	NULL
total	NULL
cellular	NULL
RNA	NULL
(	NULL
20	NULL
g	NULL
per	NULL
lane	NULL
)	NULL
was	NULL
blotted	NULL
and	NULL
hybridized	NULL
to	NULL
the	NULL
indicated	NULL
*Â°P-labelled	NULL
cDNA	NULL
probes	NULL
.	NULL

showed	NULL
that	NULL
upregulation	NULL
of	NULL
PML	NULL
mRNA	NULL
levels	NULL
was	NULL
already	NULL
evident	NULL
upon	NULL
incubation	NULL
w	NULL
ith	NULL
30	NULL
IU/ml	NULL
IFN	NULL
Â«	NULL
@	NULL
for	NULL
6	NULL
h	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
.	NULL

At	NULL
IFNG	NULL
doses	NULL
of	NULL
30	NULL
IU/ml	NULL
and	NULL
3000	NULL
IU/	NULL
ml	NULL
,	NULL
quantitative	NULL
analysis	NULL
employing	NULL
densitometric	NULL
scanning	NULL
revealed	NULL
a	NULL
3.2	NULL
fold	NULL
and	NULL
a	NULL
5.3	NULL
fold	NULL
induction	NULL
of	NULL
PML	NULL
mRNA	NULL
levels	NULL
,	NULL
respectively	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
.	NULL

As	NULL
a	NULL
control	NULL
,	NULL
PML	NULL
transcriptlevels	NULL
were	NULL
monitored	NULL
upon	NULL
incubation	NULL
for	NULL
6h	NULL
with	NULL
TNFG	NULL
and	NULL
LPS	NULL
and	NULL
were	NULL
found	NULL
to	NULL
be	NULL
unchanged	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
.	NULL

In	NULL
ex	NULL
periments	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
and	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
investigating	NULL
the	NULL
kinetics	NULL
of	NULL
IFN	NULL
induced	NULL
PML	NULL
mRNA	NULL
upregulation	NULL
in	NULL
PBMNC	NULL
,	NULL
maximum	NULL
enhancement	NULL
of	NULL
PML	NULL
transcript	NULL
expression	NULL
was	NULL
already	NULL
observed	NULL
upon	NULL
incubation	NULL
for	NULL
3	NULL
h	NULL
(	NULL
3000	NULL
IU/ml	NULL
IEN	NULL
)	NULL
.	NULL

Thereafter	NULL
PML	NULL
transcript	NULL
levels	NULL
declined	NULL
and	NULL
were	NULL
barely	NULL
visible	NULL
after	NULL
24h	NULL
despite	NULL
continuous	NULL
PML	NULL
B-actin	NULL
FIG	NULL
.	NULL

3	NULL
.	NULL

Northern	NULL
blot	NULL
analysis	NULL
of	NULL
PML-specific	NULL
mRNA	NULL
levels	NULL
from	NULL
IFN-	NULL
Â«	NULL
and	NULL
IFN-y	NULL
treated	NULL
HL6O	NULL
cells	NULL
.	NULL

HL6O	NULL
cells	NULL
were	NULL
treated	NULL
with	NULL
IFN-	NULL
Â«	NULL
(	NULL
1000	NULL
or	NULL
IFN-y	NULL
(	NULL
1000	NULL
U/m	NULL
!	NULL
)	NULL

for	NULL
the	NULL
indicated	NULL
time	NULL
or	NULL
were	NULL
left	NULL
untreated	NULL
.	NULL

Northern	NULL
blotting	NULL
was	NULL
performed	NULL
as	NULL
described	NULL
above	NULL
.	NULL

Densitometric	NULL
scanning	NULL
revealed	NULL
a	NULL
2.5-fold	NULL
and	NULL
1.9-fold	NULL
induction	NULL
of	NULL
PML-mRNA	NULL
levels	NULL
upon	NULL
incubation	NULL
for	NULL
2h	NULL
with	NULL
IFN-	NULL
Â«	NULL
(	NULL
1000	NULL
1U/m	NULL
!	NULL
)	NULL

and	NULL
IFN-y	NULL
(	NULL
1000	NULL
1U/m	NULL
!	NULL
)	NULL

,	NULL
respectively	NULL
.	NULL

Incubation	NULL
for	NULL
6h	NULL
with	NULL
IFN-	NULL
Â«	NULL
(	NULL
1000	NULL
1U/m	NULL
!	NULL
)	NULL

and	NULL
IFN-y	NULL
(	NULL
1000	NULL
IU/m	NULL
!	NULL
)	NULL

showed	NULL
a	NULL
25.4-fold	NULL
and	NULL
a	NULL
27	NULL
4-fold	NULL
induction	NULL
of	NULL
PML-specific	NULL
transcript	NULL
levels	NULL
.	NULL

incubation	NULL
with	NULL
3000	NULL
IU/ml	NULL
IFN	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
to	NULL
IFN	NULL
,	NULL
IFNLB	NULL
(	NULL
3000	NULL
IU/ml	NULL
!	NULL
)	NULL

induced	NULL
PML	NULL
transcript	NULL
induction	NULL
increased	NULL
gradually	NULL
over	NULL
time	NULL
and	NULL
maximum	NULL
enhancement	NULL
was	NULL
reached	NULL
at	NULL
24h	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
.	NULL

The	NULL
time	NULL
course	NULL
of	NULL
IFN-y	NULL
induced	NULL
PML	NULL
transcript	NULL
enhancement	NULL
during	NULL
a	NULL
6-hincubation	NULL
period	NULL
was	NULL
similar	NULL
to	NULL
IFNG	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
)	NULL
.	NULL

Previous	NULL
studies	NULL
indicated	NULL
that	NULL
transcriptional	NULL
regulation	NULL
of	NULL
the	NULL
PML	NULL
gene	NULL
is	NULL
involved	NULL
in	NULL
up-regulation	NULL
of	NULL
PML	NULL
mRNA	NULL
by	NULL
IFNs	NULL
.	NULL
'	NULL

''	NULL
``	NULL
Â°	NULL
To	NULL
confirm	NULL
that	NULL
IFNinduced	NULL
modulation	NULL
of	NULL
PML	NULL
mRNA	NULL
is	NULL
independent	NULL
from	NULL
de	NULL
novo	NULL
protein	NULL
synthesis	NULL
,	NULL
we	NULL
performed	NULL
PML	NULL
B-actin	NULL
FIG	NULL
.	NULL

4	NULL
.	NULL

Induction	NULL
of	NULL
PML-specific	NULL
mRNA	NULL
by	NULL
IL-1	NULL
Â«	NULL
and	NULL
IFN-	NULL
Â«	NULL
.	NULL

Human	NULL
diploid	NULL
foreskin	NULL
fibroblasts	NULL
were	NULL
treated	NULL
with	NULL
IL-1	NULL
(	NULL
100	NULL
IU/m	NULL
!	NULL
)	NULL

,	NULL
with	NULL
IFN-	NULL
Â«	NULL
(	NULL
1000	NULL
1U/m	NULL
!	NULL
)	NULL

or	NULL
with	NULL
a	NULL
combination	NULL
of	NULL
IFN-	NULL
Â«	NULL
(	NULL
1000	NULL
1U/m	NULL
!	NULL
)	NULL

and	NULL
IL-1	NULL
Â«	NULL
(	NULL
100	NULL
1U/m	NULL
!	NULL
)	NULL

for	NULL
6h	NULL
.	NULL

Cells	NULL
were	NULL
grown	NULL
in	NULL
the	NULL
absence	NULL
or	NULL
presence	NULL
of	NULL
an	NULL
inhibitor	NULL
of	NULL
protein	NULL
tyrosine	NULL
kinases	NULL
(	NULL
genistein	NULL
50	NULL
ug/ml	NULL
)	NULL
.	NULL

Northern	NULL
blotting	NULL
was	NULL
performed	NULL
as	NULL
described	NULL
above	NULL
.	NULL

For	NULL
quantitative	NULL
analysis	NULL
,	NULL
PML-specific	NULL
transcript	NULL
levels	NULL
were	NULL
analysed	NULL
by	NULL
densitometric	NULL
scanning	NULL
and	NULL
normalized	NULL
to	NULL
B-actin	NULL
mRNA	NULL
expression	NULL
as	NULL
described	NULL
in	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL

Mediators	NULL
of	NULL
Inflammation	NULL
-	NULL
Vol	NULL
7	NULL
-	NULL
1998	NULL
321	NULL
M.	NULL
Heuser	NULL
et	NULL
al	NULL
.	NULL

Northern	NULL
blot	NULL
analyses	NULL
with	NULL
and	NULL
without	NULL
an	NULL
inhibitor	NULL
of	NULL
protein	NULL
synthesis	NULL
(	NULL
CHX	NULL
)	NULL
.	NULL

These	NULL
experiments	NULL
demonstrated	NULL
that	NULL
CHX	NULL
had	NULL
no	NULL
effect	NULL
on	NULL
IFNinduced	NULL
upregulation	NULL
of	NULL
PML	NULL
mRNA	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

The	NULL
influence	NULL
of	NULL
IL-IQ	NULL
on	NULL
PML	NULL
transcript	NULL
expression	NULL
was	NULL
investigated	NULL
in	NULL
human	NULL
foreskin	NULL
fibroblasts	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
)	NULL
.	NULL

Treatment	NULL
with	NULL
IL1Q	NULL
at	NULL
a	NULL
dose	NULL
of	NULL
100	NULL
IU/ml	NULL
!	NULL

for	NULL
6h	NULL
resulted	NULL
in	NULL
a	NULL
3.8fold	NULL
upregulation	NULL
of	NULL
PMLspecific	NULL
mRNA	NULL
levels	NULL
as	NULL
analysed	NULL
by	NULL
densitometric	NULL
scanning	NULL
.	NULL

A	NULL
more	NULL
pronounced	NULL
enhancement	NULL
of	NULL
PML	NULL
transcript	NULL
levels	NULL
(	NULL
7.1fold	NULL
induction	NULL
)	NULL
was	NULL
observed	NULL
incubated	NULL
with	NULL
IFN	NULL
.	NULL

IL-1	NULL
in	NULL
combination	NULL
with	NULL
IFN	NULL
stimulated	NULL
PML	NULL
mRNA	NULL
expression	NULL
to	NULL
more	NULL
than	NULL
twice	NULL
the	NULL
level	NULL
obtained	NULL
w	NULL
ith	NULL
IEN	NULL
alone	NULL
(	NULL
15.3	NULL
fold	NULL
induction	NULL
relative	NULL
to	NULL
medium	NULL
control	NULL
)	NULL
,	NULL
as	NULL
estimated	NULL
by	NULL
densitometric	NULL
scanning	NULL
.	NULL

Co-incubation	NULL
with	NULL
genistein,17	NULL
an	NULL
inhibitor	NULL
of	NULL
tyrosine	NULL
kinases	NULL
,	NULL
significantly	NULL
inhibited	NULL
the	NULL
IFNinduced	NULL
increase	NULL
in	NULL
the	NULL
level	NULL
of	NULL
PML	NULL
transcripts	NULL
,	NULL
whereas	NULL
no	NULL
effect	NULL
of	NULL
genistein	NULL
on	NULL
IL-1	NULL
induced	NULL
PML	NULL
mRNA	NULL
expression	NULL
was	NULL
noted	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
)	NULL
.	NULL

Similar	NULL
results	NULL
were	NULL
obtained	NULL
using	NULL
the	NULL
amnion	NULL
fibroblast	NULL
cell	NULL
line	NULL
WISH	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

when	NULL
CCHS	NULL
were	NULL
Influence	NULL
of	NULL
IFN-	NULL
Â«	NULL
on	NULL
PML	NULL
protein	NULL
expression	NULL
In	NULL
an	NULL
attempt	NULL
to	NULL
investigate	NULL
modulation	NULL
of	NULL
PLM	NULL
protein	NULL
expression	NULL
,	NULL
we	NULL
performed	NULL
flow	NULL
cytometry	NULL
>	NULL
_SINGLE	NULL
PARAMETER	NULL
isotype	NULL
control	NULL
y-axis	NULL
126	NULL
169	NULL
84	NULL
42	NULL
1	NULL
1	NULL
10	NULL
100	NULL
1000	NULL
x-axis	NULL
B	NULL
:	NULL
_	NULL
,	NULL
_	NULL
SINGLE	NULL
PaRAMETER	NULL
a	NULL
ID	NULL
ï¬g	NULL
isotype	NULL
control	NULL
1	NULL
>	NULL
r	NULL
122	NULL
193	NULL
61	NULL
la	NULL
T4	NULL
0000	NULL
de	NULL
O0	NULL
00	NULL
bee	NULL
___	NULL
igee	NULL
x-axis	NULL
FIG	NULL
.	NULL

5	NULL
.	NULL

Induction	NULL
of	NULL
PML	NULL
protein	NULL
by	NULL
IFN-	NULL
Â«	NULL
in	NULL
HL6O	NULL
cells	NULL
.	NULL

HL6O	NULL
cells	NULL
were	NULL
treated	NULL
with	NULL
(	NULL
B	NULL
)	NULL
and	NULL
without	NULL
(	NULL
A	NULL
)	NULL
IFN-	NULL
Â«	NULL
(	NULL
1000	NULL
1U/m	NULL
!	NULL
)	NULL

for	NULL
18h	NULL
.	NULL

Expression	NULL
of	NULL
PML	NULL
protein	NULL
was	NULL
analysed	NULL
by	NULL
flow	NULL
cytometry	NULL
using	NULL
a	NULL
specific	NULL
monoclonal	NULL
anti-PML	NULL
antibody	NULL
as	NULL
descibed	NULL
in	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL

Normal	NULL
mouse	NULL
IgG	NULL
was	NULL
used	NULL
as	NULL
isotype	NULL
control	NULL
.	NULL

322	NULL
Mediators	NULL
of	NULL
Inflammation	NULL
-	NULL
Vol	NULL
7	NULL
-	NULL
1998	NULL
Ac	NULL
B	NULL
:	NULL
smote	NULL
povo	NULL
flisotype	NULL
control	NULL
[	NULL
A	NULL
â	NULL
H	NULL
<	NULL
-	NULL
PG-M3	NULL
I	NULL
y-axio	NULL
y-axia	NULL
t	NULL
a	NULL
1	NULL
in	NULL
am	NULL
ioe	NULL
x-azin	NULL
time	NULL
{	NULL
1000	NULL
TU	NULL
IFNo	NULL
)	NULL
â	NULL
med	NULL
.	NULL

(	NULL
A	NULL
:	NULL
)	NULL
â	NULL
6h	NULL
!	NULL

AMeanX	NULL
â	NULL
25	NULL
24	NULL
â	NULL
25	NULL
â	NULL
3,8	NULL
|	NULL
43	NULL
FIG	NULL
.	NULL

6	NULL
.	NULL

Kinetics	NULL
of	NULL
induction	NULL
of	NULL
PML	NULL
protein	NULL
by	NULL
IFN-	NULL
Â«	NULL
in	NULL
U937	NULL
cells	NULL
U937	NULL
cells	NULL
were	NULL
treated	NULL
with	NULL
and	NULL
without	NULL
IFN-	NULL
Â«	NULL
(	NULL
1000	NULL
1U/m	NULL
!	NULL
)	NULL

for	NULL
the	NULL
indicated	NULL
time	NULL
(	NULL
A	NULL
:	NULL
;	NULL
medium	NULL
control	NULL
;	NULL
B	NULL
:	NULL
IFN-	NULL
Â«	NULL
for	NULL
19.5h	NULL
)	NULL
.	NULL

Induction	NULL
of	NULL
PML	NULL
protein	NULL
was	NULL
monitored	NULL
by	NULL
flow	NULL
cytometry	NULL
using	NULL
a	NULL
specific	NULL
monoclonal	NULL
antibody	NULL
recognizing	NULL
the	NULL
aminoterminal	NULL
domain	NULL
of	NULL
PML	NULL
as	NULL
described	NULL
in	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL

Normal	NULL
mouse	NULL
IgG	NULL
was	NULL
used	NULL
as	NULL
isotype	NULL
control	NULL
.	NULL

Given	NULL
is	NULL
the	NULL
mean	NULL
log	NULL
specific	NULL
fluorescence	NULL
intensity	NULL
as	NULL
described	NULL
in	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL

analyses	NULL
.	NULL

IFN	NULL
treatment	NULL
of	NULL
the	NULL
three	NULL
myeloid	NULL
cell	NULL
lines	NULL
HL60	NULL
,	NULL
NB4	NULL
and	NULL
U937	NULL
resulted	NULL
in	NULL
upregulation	NULL
of	NULL
PML	NULL
protein	NULL
expression	NULL
.	NULL

For	NULL
example	NULL
,	NULL
in	NULL
HL6O0	NULL
cells	NULL
,	NULL
upregulation	NULL
of	NULL
PML	NULL
ex	NULL
pression	NULL
was	NULL
detectable	NULL
upon	NULL
incubation	NULL
with	NULL
IFNG	NULL
for	NULL
18h	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
)	NULL
.	NULL

The	NULL
time	NULL
course	NULL
of	NULL
IFN-induced	NULL
enhancement	NULL
of	NULL
PML	NULL
protein	NULL
expression	NULL
was	NULL
monitored	NULL
in	NULL
U937	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

6	NULL
)	NULL
.	NULL

Induction	NULL
of	NULL
PML	NULL
was	NULL
not	NULL
detectable	NULL
upon	NULL
incubation	NULL
with	NULL
IFN	NULL
Â«	NULL
@	NULL
(	NULL
10001U/m	NULL
!	NULL

l	NULL
)	NULL
for	NULL
only	NULL
6h	NULL
or	NULL
12h	NULL
but	NULL
started	NULL
thereafter	NULL
and	NULL
reached	NULL
a	NULL
plateau	NULL
at	NULL
20	NULL
h	NULL
(	NULL
Fig	NULL
.	NULL

6	NULL
and	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Dose-response	NULL
experiments	NULL
in	NULL
U937	NULL
cells	NULL
revealed	NULL
that	NULL
incubation	NULL
with	NULL
10	NULL
U/ml	NULL
IFN-4	NULL
for	NULL
20	NULL
h	NULL
already	NULL
resulted	NULL
in	NULL
slight	NULL
upregulation	NULL
of	NULL
PML	NULL
protein	NULL
expression	NULL
to	NULL
113	NULL
%	NULL
of	NULL
the	NULL
untreated	NULL
control	NULL
(	NULL
Fig	NULL
.	NULL

7	NULL
)	NULL
.	NULL

Maximum	NULL
upregulation	NULL
of	NULL
PML	NULL
expression	NULL
to	NULL
160	NULL
%	NULL
of	NULL
that	NULL
of	NULL
untreated	NULL
cells	NULL
was	NULL
achieved	NULL
by	NULL
incubation	NULL
with	NULL
doses	NULL
greater	NULL
than	NULL
500	NULL
IU/ml	NULL
IFN	NULL
(	NULL
Fig	NULL
.	NULL

7	NULL
)	NULL
.	NULL

These	NULL
data	NULL
indicate	NULL
that	NULL
half	NULL
PML	NULL
specific	NULL
immunfluorescence	NULL
intensity	NULL
(	NULL
AMeanX	NULL
)	NULL
0	NULL
10	NULL
50	NULL
100	NULL
500	NULL
1000	NULL
IFNet	NULL
(	NULL
W/m	NULL
!	NULL
)	NULL

FIG	NULL
.	NULL

7	NULL
.	NULL

Dose-response	NULL
of	NULL
induction	NULL
of	NULL
PML	NULL
protein	NULL
by	NULL
IFN-	NULL
Â«	NULL
in	NULL
U937	NULL
cells	NULL
.	NULL

U937	NULL
cells	NULL
were	NULL
incubated	NULL
for	NULL
18h	NULL
in	NULL
the	NULL
absence	NULL
or	NULL
presence	NULL
of	NULL
the	NULL
indicated	NULL
dose	NULL
of	NULL
IFN-	NULL
Â«	NULL
and	NULL
PML	NULL
protein	NULL
expression	NULL
was	NULL
analysed	NULL
by	NULL
flow	NULL
cytometry	NULL
using	NULL
a	NULL
specific	NULL
monoclonal	NULL
antibody	NULL
as	NULL
described	NULL
in	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL

Given	NULL
is	NULL
the	NULL
mean	NULL
log	NULL
specific	NULL
fluorescence	NULL
intensity	NULL
as	NULL
described	NULL
in	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL

PML	NULL
gene	NULL
expression	NULL
is	NULL
upregulated	NULL
by	NULL
interferons	NULL
and	NULL
IL-1	NULL
Table	NULL
1	NULL
.	NULL

Induction	NULL
of	NULL
PML	NULL
protein	NULL
by	NULL
IFN-	NULL
Â«	NULL
,	NULL
IL-i	NULL
Â«	NULL
or	NULL
a	NULL
combination	NULL
of	NULL
both	NULL
in	NULL
human	NULL
diploid	NULL
fibroblasts	NULL
Treatment	NULL
A	NULL
fold	NULL
Mean	NULL
X	NULL
-	NULL
induction	NULL
Medium	NULL
1.29	NULL
1.0	NULL
IFN-	NULL
Â«	NULL
.	NULL

(	NULL
100	NULL
IU/m	NULL
!	NULL
)	NULL

2.75	NULL
2.1	NULL
IL-	NULL
1	NULL
Â«	NULL
(	NULL
100	NULL
1U/m	NULL
!	NULL

1	NULL
)	NULL
2.31	NULL
1.8	NULL
IL-	NULL
1	NULL
Â«	NULL
(	NULL
1000	NULL
1U/m	NULL
!	NULL

1	NULL
)	NULL
2.43	NULL
1.9	NULL
IFN-	NULL
Â«	NULL
(	NULL
100	NULL
IU/m	NULL
!	NULL
)	NULL

+1L-1	NULL
Â«	NULL
(	NULL
100	NULL
1U/m	NULL
!	NULL
)	NULL

4.30	NULL
3.3	NULL
IFN-	NULL
Â«	NULL
(	NULL
100	NULL
IU/m	NULL
!	NULL
)	NULL

+1L-1	NULL
Â«	NULL
(	NULL
1000	NULL
IU/m	NULL
!	NULL
)	NULL

3.80	NULL
3.0	NULL
Fibroblasts	NULL
were	NULL
incubated	NULL
with	NULL
and	NULL
without	NULL
the	NULL
indicated	NULL
cytokines	NULL
at	NULL
the	NULL
indicated	NULL
dose	NULL
for	NULL
21.5h	NULL
.	NULL

Induction	NULL
of	NULL
PML	NULL
protein	NULL
expression	NULL
was	NULL
analysed	NULL
by	NULL
flow	NULL
cytometry	NULL
using	NULL
a	NULL
specific	NULL
anti-PML	NULL
monoclonal	NULL
mouse	NULL
antibody	NULL
and	NULL
normal	NULL
mouse	NULL
IgG	NULL
as	NULL
control	NULL
as	NULL
described	NULL
above	NULL
.	NULL

Given	NULL
is	NULL
the	NULL
mean	NULL
log	NULL
specific	NULL
fluorescence	NULL
intensity	NULL
as	NULL
described	NULL
in	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL

maximum	NULL
IFN	NULL
response	NULL
is	NULL
reached	NULL
at	NULL
50	NULL
U/ml	NULL
IFN	NULL
Â«	NULL
@	NULL
which	NULL
corresponds	NULL
to	NULL
the	NULL
IFN	NULL
concentration	NULL
needed	NULL
to	NULL
achieve	NULL
a	NULL
half	NULL
maximum	NULL
response	NULL
in	NULL
other	NULL
biological	NULL
activities	NULL
of	NULL
IFN	NULL
Â«	NULL
.	NULL

!	NULL

``	NULL
Â°	NULL
When	NULL
human	NULL
foreskin	NULL
fibroblasts	NULL
were	NULL
grown	NULL
in	NULL
the	NULL
absence	NULL
or	NULL
or	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
saturating	NULL
concentrations	NULL
of	NULL
IL-1	NULL
,	NULL
a	NULL
nearly	NULL
twofold	NULL
increase	NULL
of	NULL
PML	NULL
protein	NULL
expression	NULL
was	NULL
detected	NULL
by	NULL
flow	NULL
cytometry	NULL
analysis	NULL
(	NULL
Table	NULL
1	NULL
)	NULL
.	NULL

A	NULL
similar	NULL
result	NULL
was	NULL
obtained	NULL
upon	NULL
incubation	NULL
with	NULL
IFN	NULL
(	NULL
100	NULL
IU/ml	NULL
)	NULL
.	NULL

The	NULL
combination	NULL
of	NULL
IL-1	NULL
and	NULL
IFN	NULL
stimulated	NULL
PML	NULL
protein	NULL
expression	NULL
to	NULL
about	NULL
three	NULL
times	NULL
the	NULL
level	NULL
observed	NULL
in	NULL
untreated	NULL
controls	NULL
(	NULL
Table	NULL
1	NULL
)	NULL
.	NULL

Analysis	NULL
of	NULL
PML	NULL
nuclear	NULL
bodies	NULL
Since	NULL
it	NULL
has	NULL
been	NULL
show	NULL
n	NULL
that	NULL
PML	NULL
proteins	NULL
are	NULL
located	NULL
within	NULL
subnuclear	NULL
structures	NULL
from	NULL
active	NULL
sites	NULL
of	NULL
transcription	NULL
and	NULL
splicing	NULL
,	NULL
the	NULL
so-called	NULL
PML	NULL
nuclear	NULL
bodies	NULL
were	NULL
monitored	NULL
during	NULL
IFN	NULL
treatment	NULL
using	NULL
indirect	NULL
immunofluorescence	NULL
staining	NULL
.	NULL

PMLspecific	NULL
immunofluotrescence	NULL
varied	NULL
in	NULL
intensity	NULL
between	NULL
the	NULL
cell	NULL
lines	NULL
tested	NULL
.	NULL

In	NULL
all	NULL
cell	NULL
lines	NULL
tested	NULL
(	NULL
NB4	NULL
,	NULL
HL6O0	NULL
,	NULL
U937	NULL
)	NULL
and	NULL
in	NULL
peripheral	NULL
blood	NULL
leukocytes	NULL
the	NULL
con-stitutive	NULL
levels	NULL
of	NULL
endogenous	NULL
proteins	NULL
were	NULL
detectable	NULL
(	NULL
Figs	NULL
8	NULL
and	NULL
9	NULL
)	NULL
.	NULL

Peripheral	NULL
blood	NULL
leukocytes	NULL
revealed	NULL
specific	NULL
immunolabelling	NULL
of	NULL
PML	NULL
nuclear	NULL
bodies	NULL
in	NULL
neutrophils	NULL
and	NULL
monocytes	NULL
(	NULL
Fig	NULL
.	NULL

8	NULL
)	NULL
.	NULL

When	NULL
HL6O0	NULL
and	NULL
U937	NULL
cells	NULL
were	NULL
incubated	NULL
for	NULL
15h	NULL
with	NULL
and	NULL
without	NULL
IFNG	NULL
(	NULL
1000	NULL
U/ml	NULL
!	NULL
)	NULL

a	NULL
marked	NULL
enhancement	NULL
of	NULL
the	NULL
immunolabelling	NULL
was	NULL
observed	NULL
in	NULL
treated	NULL
cells	NULL
.	NULL

Both	NULL
the	NULL
intensity	NULL
of	NULL
the	NULL
staining	NULL
and	NULL
the	NULL
number	NULL
of	NULL
the	NULL
labelled	NULL
PML	NULL
nuclear	NULL
bodies	NULL
was	NULL
increased	NULL
significantly	NULL
(	NULL
Fig	NULL
.	NULL

9	NULL
and	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Discussion	NULL
Our	NULL
data	NULL
confirm	NULL
and	NULL
extend	NULL
previous	NULL
studies	NULL
demonstrating	NULL
that	NULL
cytokines	NULL
are	NULL
involved	NULL
in	NULL
modulation	NULL
of	NULL
PML	NULL
gene	NULL
expression.15	NULL
â	NULL
16	NULL
We	NULL
show	NULL
that	NULL
PML	NULL
transcripts	NULL
rapidly	NULL
accumulate	NULL
upon	NULL
treatment	NULL
with	NULL
interferons	NULL
in	NULL
a	NULL
variety	NULL
of	NULL
haematopoietic	NULL
cell	NULL
lines	NULL
and	NULL
in	NULL
primary	NULL
diploid	NULL
cells	NULL
.	NULL

However	NULL
,	NULL
our	NULL
experiments	NULL
demonstrate	NULL
a	NULL
marked	NULL
difference	NULL
in	NULL
the	NULL
time	NULL
course	NULL
of	NULL
PML-mRNA	NULL
induction	NULL
between	NULL
IFNÂ®G	NULL
and	NULL
IFN	NULL
.	NULL

Induction	NULL
of	NULL
PML	NULL
in	NULL
response	NULL
to	NULL
IFN	NULL
was	NULL
shown	NULL
to	NULL
be	NULL
independent	NULL
from	NULL
de	NULL
novo	NULL
protein	NULL
synthesis	NULL
and	NULL
actinomycin	NULL
sensitive	NULL
indicating	NULL
that	NULL
PML	NULL
mRNA	NULL
levels	NULL
are	NULL
transcriptionally	NULL
regulated	NULL
by	NULL
IENs	NULL
.	NULL
``	NULL

''	NULL
Recently	NULL
,	NULL
evidence	NULL
has	NULL
been	NULL
provided	NULL
that	NULL
the	NULL
PML	NULL
gene	NULL
is	NULL
transcriptionally	NULL
upregulated	NULL
by	NULL
IFNs	NULL
through	NULL
activation	NULL
and	NULL
binding	NULL
of	NULL
STATs	NULL
to	NULL
an	NULL
ISRE	NULL
and	NULL
a	NULL
GAS	NULL
element	NULL
in	NULL
the	NULL
untranslated	NULL
first	NULL
exon	NULL
.	NULL
``	NULL

IENs	NULL
activate	NULL
STATS	NULL
through	NULL
tyrosine	NULL
phosphorylation	NULL
by	NULL
members	NULL
of	NULL
the	NULL
JAK	NULL
tyrosine	NULL
kinase	NULL
family.19	NULL
Our	NULL
results	NULL
demonstrating	NULL
inhibition	NULL
of	NULL
IFN-induced	NULL
upregulation	NULL
of	NULL
PML	NULL
transcripts	NULL
by	NULL
the	NULL
tyrosine	NULL
kinase	NULL
inhibitor	NULL
genistein	NULL
are	NULL
consistent	NULL
with	NULL
these	NULL
findings	NULL
.	NULL

Flow	NULL
cytometry	NULL
analyses	NULL
using	NULL
a	NULL
specific	NULL
monoclonal	NULL
anti-PML	NULL
antibody	NULL
recognizing	NULL
the	NULL
aminoterminal	NULL
domain	NULL
clearly	NULL
demonstrate	NULL
that	NULL
IFNs	NULL
induce	NULL
PML	NULL
(	NULL
A	NULL
)	NULL
(	NULL
B	NULL
)	NULL
FIG	NULL
.	NULL

8	NULL
.	NULL

In	NULL
situ	NULL
immunofluorescence	NULL
analysis	NULL
of	NULL
PML	NULL
proteins	NULL
in	NULL
human	NULL
peripheral	NULL
blood	NULL
leukocytes	NULL
.	NULL

Indirect	NULL
immunofluorescence	NULL
analysis	NULL
of	NULL
a	NULL
peripheral	NULL
blood	NULL
smear	NULL
was	NULL
performed	NULL
using	NULL
the	NULL
specific	NULL
mouse	NULL
monoclonal	NULL
antibody	NULL
PG-M3	NULL
(	NULL
B	NULL
)	NULL
and	NULL
normal	NULL
mouse	NULL
IgG	NULL
(	NULL
A	NULL
)	NULL
as	NULL
control	NULL
as	NULL
described	NULL
in	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL

Specific	NULL
immunolabelling	NULL
can	NULL
be	NULL
detected	NULL
in	NULL
neutrophils	NULL
and	NULL
monocytes	NULL
which	NULL
were	NULL
identified	NULL
by	NULL
morphologic	NULL
criteria	NULL
.	NULL

Mediators	NULL
of	NULL
Inflammation	NULL
-	NULL
Vol	NULL
7	NULL
-	NULL
1998	NULL
323	NULL
M.	NULL
Heuser	NULL
et	NULL
al	NULL
.	NULL

(	NULL
A	NULL
)	NULL
(	NULL
C	NULL
)	NULL
(	NULL
B	NULL
)	NULL
(	NULL
D	NULL
)	NULL
FIG	NULL
.	NULL

9	NULL
.	NULL

In	NULL
situ	NULL
immunofluorescence	NULL
analysis	NULL
of	NULL
PLM	NULL
proteins	NULL
in	NULL
HL6O	NULL
cells	NULL
.	NULL

HL6O	NULL
cells	NULL
were	NULL
incubated	NULL
with	NULL
(	NULL
C	NULL
,	NULL
D	NULL
)	NULL
and	NULL
without	NULL
(	NULL
A	NULL
,	NULL
B	NULL
)	NULL
IFN-	NULL
Â«	NULL
(	NULL
1000	NULL
IU/m	NULL
!	NULL
)	NULL

for	NULL
15h	NULL
.	NULL

Indirect	NULL
immunofluorescence	NULL
analysis	NULL
was	NULL
performed	NULL
using	NULL
the	NULL
specific	NULL
mouse	NULL
monoclonal	NULL
!	NULL

antibody	NULL
PG-M3	NULL
(	NULL
B	NULL
,	NULL
D	NULL
)	NULL
and	NULL
normal	NULL
mouse	NULL
IgG	NULL
(	NULL
A	NULL
,	NULL
C	NULL
)	NULL
as	NULL
control	NULL
as	NULL
described	NULL
in	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL

protein	NULL
in	NULL
a	NULL
dose	NULL
dependent	NULL
manner	NULL
.	NULL

Recently	NULL
,	NULL
it	NULL
has	NULL
been	NULL
shown	NULL
that	NULL
PML	NULL
protein	NULL
expression	NULL
has	NULL
a	NULL
speckled	NULL
nuclear	NULL
pattern.15This	NULL
is	NULL
due	NULL
to	NULL
localization	NULL
of	NULL
the	NULL
protein	NULL
in	NULL
pootly	NULL
defined	NULL
nuclear	NULL
organelles	NULL
named	NULL
nuclear	NULL
bodies	NULL
.	NULL

The	NULL
functions	NULL
of	NULL
the	NULL
nuclear	NULL
bodies	NULL
are	NULL
unknown	NULL
except	NULL
for	NULL
the	NULL
coiled	NULL
bodies	NULL
which	NULL
act	NULL
as	NULL
storage	NULL
compartments	NULL
for	NULL
splicing	NULL
factors	NULL
.	NULL
``	NULL

''	NULL
To	NULL
analyse	NULL
expression	NULL
of	NULL
PML	NULL
proteins	NULL
within	NULL
nuclear	NULL
bodies	NULL
we	NULL
performed	NULL
indirect	NULL
in	NULL
site	NULL
immunofluorescence	NULL
studies	NULL
.	NULL

/n	NULL
site	NULL
immunolabelling	NULL
of	NULL
PML	NULL
protein	NULL
expression	NULL
revealed	NULL
an	NULL
IFNinduced	NULL
increase	NULL
in	NULL
number	NULL
and	NULL
intensity	NULL
of	NULL
so-called	NULL
PML	NULL
nuclear	NULL
bodies	NULL
.	NULL

To	NULL
the	NULL
best	NULL
of	NULL
our	NULL
knowledge	NULL
induction	NULL
of	NULL
PML	NULL
by	NULL
IL-1	NULL
has	NULL
not	NULL
been	NULL
described	NULL
so	NULL
far	NULL
.	NULL

Here	NULL
we	NULL
show	NULL
that	NULL
IL-1G	NULL
rapidly	NULL
induces	NULL
PML	NULL
mRNA	NULL
expression	NULL
in	NULL
fibroblasts	NULL
.	NULL

Since	NULL
IL-1	NULL
is	NULL
a	NULL
potent	NULL
inducer	NULL
of	NULL
IFN	NULL
and	NULL
IFNâB21	NULL
it	NULL
could	NULL
be	NULL
argued	NULL
that	NULL
the	NULL
observed	NULL
induction	NULL
of	NULL
PML	NULL
mRNA	NULL
ex	NULL
pression	NULL
is	NULL
a	NULL
consequence	NULL
of	NULL
IL-1	NULL
induced	NULL
autocrine	NULL
production	NULL
of	NULL
interferon-	NULL
.	NULL

We	NULL
addressed	NULL
this	NULL
issue	NULL
by	NULL
employing	NULL
the	NULL
tyrosine	NULL
kinase	NULL
inhibitor	NULL
genistein	NULL
.	NULL

Genistein	NULL
was	NULL
show	NULL
n	NULL
to	NULL
strongly	NULL
inhibit	NULL
IFN	NULL
signalling.17	NULL
Our	NULL
experiments	NULL
clearly	NULL
show	NULL
that	NULL
in	NULL
fibroblasts	NULL
genistein	NULL
is	NULL
not	NULL
able	NULL
to	NULL
suppress	NULL
the	NULL
IL-1	NULL
induced	NULL
upregulation	NULL
of	NULL
PML	NULL
324	NULL
Mediators	NULL
of	NULL
Inflammation	NULL
-	NULL
Vol	NULL
7	NULL
-	NULL
1998	NULL
transcripts	NULL
,	NULL
whereas	NULL
IFNinduced	NULL
enhancement	NULL
of	NULL
PMLspecific	NULL
transcripts	NULL
was	NULL
strongly	NULL
inhibited	NULL
.	NULL

Thus	NULL
,	NULL
indirect	NULL
regulation	NULL
of	NULL
PML	NULL
by	NULL
IL-1	NULL
induced	NULL
autocrine	NULL
production	NULL
of	NULL
appears	NULL
unlikely	NULL
.	NULL

Flow	NULL
cytometry	NULL
analysis	NULL
revealed	NULL
that	NULL
IL-1	NULL
and	NULL
IFN-	NULL
act	NULL
synergistically	NULL
in	NULL
induction	NULL
of	NULL
PML	NULL
proteins	NULL
.	NULL

This	NULL
regulation	NULL
could	NULL
be	NULL
involved	NULL
in	NULL
the	NULL
observed	NULL
upregulation	NULL
of	NULL
PML	NULL
proteins	NULL
in	NULL
inflammation	NULL
.	NULL

In	NULL
contrast	NULL
to	NULL
normal	NULL
tissues	NULL
,	NULL
in	NULL
inflammatory	NULL
tissues	NULL
the	NULL
level	NULL
of	NULL
PML	NULL
proteins	NULL
is	NULL
upregulatecl.7	NULL
â	NULL
8	NULL
Local	NULL
production	NULL
of	NULL
IL-1	NULL
has	NULL
been	NULL
demonstrated	NULL
in	NULL
inflammatory	NULL
and	NULL
autoimmune	NULL
disease	NULL
and	NULL
this	NULL
may	NULL
contribute	NULL
to	NULL
tissue	NULL
damage	NULL
and	NULL
repainï¬	NULL
â	NULL
22	NULL
In	NULL
fibroblasts	NULL
,	NULL
IL-1	NULL
mediates	NULL
tissue	NULL
repair	NULL
after	NULL
inflammation	NULL
and	NULL
injury	NULL
by	NULL
regulating	NULL
key	NULL
proteins	NULL
necessary	NULL
for	NULL
formation	NULL
of	NULL
the	NULL
extracellular	NULL
matrix	NULL
.	NULL
``	NULL

The	NULL
data	NULL
presented	NULL
here	NULL
suggest	NULL
that	NULL
IL-1	NULL
induced	NULL
PML	NULL
expression	NULL
may	NULL
represent	NULL
the	NULL
molecular	NULL
basis	NULL
for	NULL
the	NULL
observed	NULL
upregulation	NULL
of	NULL
PML	NULL
proteins	NULL
during	NULL
inflammation	NULL
.	NULL

IFNs	NULL
,	NULL
as	NULL
part	NULL
of	NULL
the	NULL
cytokine	NULL
netw	NULL
ork	NULL
are	NULL
indirectly	NULL
induced	NULL
by	NULL
regulators	NULL
such	NULL
as	NULL
tumour	NULL
necrosis	NULL
factor	NULL
during	NULL
immune	NULL
responses	NULL
and	NULL
inflammation	NULL
.	NULL

This	NULL
may	NULL
contribute	NULL
to	NULL
upregulation	NULL
of	NULL
PML	NULL
in	NULL
inflammatory	NULL
tissues	NULL
by	NULL
synergistic	NULL
action	NULL
of	NULL
IEN	NULL
and	NULL
IL-1	NULL
in	NULL
enhancing	NULL
PML	NULL
protein	NULL
expression	NULL
in	NULL
fibroblasts	NULL
.	NULL

PML	NULL
gene	NULL
expression	NULL
is	NULL
upregulated	NULL
by	NULL
interferons	NULL
and	NULL
IL-1	NULL
References	NULL
1	NULL
.	NULL

10	NULL
.	NULL

11	NULL
.	NULL

12	NULL
.	NULL

Grignani	NULL
E	NULL
Ferrucci	NULL
PE	NULL
Testa	NULL
U	NULL
,	NULL
et	NULL
22	NULL
The	NULL
acute	NULL
promyelocytic	NULL
leukemia-specific	NULL
PMLRARQ	NULL
fusion	NULL
protein	NULL
inhibits	NULL
differentiation	NULL
and	NULL
promotes	NULL
survival	NULL
of	NULL
myeloid	NULL
precursor	NULL
cells	NULL
.	NULL

Cel	NULL
1993	NULL
;	NULL
74	NULL
:	NULL
423-431.	NULL
.	NULL

Daniel	NULL
MT	NULL
,	NULL
Koken	NULL
M	NULL
,	NULL
RomagnÃ©	NULL
O	NULL
,	NULL
et	NULL
4/	NULL
PML	NULL
protein	NULL
expression	NULL
in	NULL
hematopoietic	NULL
and	NULL
acute	NULL
promyelocytic	NULL
leukemia	NULL
cells	NULL
.	NULL

Blood	NULL
1993	NULL
;	NULL
82	NULL
:	NULL
1858-1867.	NULL
.	NULL

Kakizuka	NULL
A	NULL
,	NULL
Miller	NULL
Jr	NULL
WH	NULL
,	NULL
Umesono	NULL
K	NULL
,	NULL
et	NULL
#	NULL
L	NULL
Chromosomal	NULL
translocation	NULL
t	NULL
(	NULL
15	NULL
;	NULL
17	NULL
)	NULL
in	NULL
human	NULL
acute	NULL
promyelocytic	NULL
leukemia	NULL
fuses	NULL
with	NULL
a	NULL
novel	NULL
putative	NULL
transcription	NULL
factor	NULL
,	NULL
PML	NULL
.	NULL

Cel	NULL
1991	NULL
;	NULL
66	NULL
:	NULL
663-674.	NULL
.	NULL

Mu	NULL
ZM	NULL
,	NULL
Chin	NULL
KV	NULL
,	NULL
Liu	NULL
JH	NULL
,	NULL
Lozano	NULL
G	NULL
,	NULL
Chang	NULL
KS	NULL
.	NULL

PML	NULL
,	NULL
a	NULL
grow	NULL
th	NULL
suppressor	NULL
distupted	NULL
in	NULL
acute	NULL
promyelocytic	NULL
leukemia	NULL
.	NULL

Mol	NULL
CH	NULL
Biol	NULL
1994	NULL
;	NULL
14	NULL
:	NULL
6858-6867.	NULL
.	NULL

Fagioli	NULL
M	NULL
,	NULL
et	NULL
Â«	NULL
L	NULL
Alternative	NULL
splicing	NULL
of	NULL
PML	NULL
transcripts	NULL
predicts	NULL
coexpression	NULL
of	NULL
several	NULL
carboxy4erminally	NULL
different	NULL
protein	NULL
isoforms	NULL
.	NULL

Oncogene	NULL
1992	NULL
;	NULL
7	NULL
:	NULL
1083-1091.	NULL
.	NULL

Wang	NULL
ZG	NULL
,	NULL
Delva	NULL
L	NULL
,	NULL
Gaboli	NULL
M	NULL
,	NULL
et	NULL
#	NULL
L	NULL
Role	NULL
of	NULL
PML	NULL
in	NULL
cell	NULL
growth	NULL
and	NULL
the	NULL
retinoic	NULL
acid	NULL
pathway	NULL
.	NULL

Science	NULL
1998	NULL
;	NULL
279	NULL
:	NULL
1547-1551.	NULL
.	NULL

Terris	NULL
B	NULL
,	NULL
Baldin	NULL
V	NULL
,	NULL
Dubois	NULL
S	NULL
,	NULL
et	NULL
4Z	NULL
PML	NULL
nuclear	NULL
bodies	NULL
are	NULL
general	NULL
targets	NULL
for	NULL
inflammation	NULL
and	NULL
Cancer	NULL
Res	NULL
1995	NULL
;	NULL
55	NULL
:	NULL
1590-1597.	NULL
cell	NULL
proliferation	NULL
.	NULL

Â«	NULL
Gambocorta	NULL
M	NULL
,	NULL
Flenghi	NULL
L	NULL
,	NULL
Fagioli	NULL
M	NULL
,	NULL
et	NULL
#	NULL
L	NULL
Heterogencous	NULL
nuclear	NULL
expression	NULL
of	NULL
the	NULL
promyelocytic	NULL
leukemia	NULL
(	NULL
PML	NULL
)	NULL
protein	NULL
in	NULL
normal	NULL
and	NULL
neoplastic	NULL
human	NULL
tissues	NULL
.	NULL

Am	NULL
J	NULL
Pathol	NULL
1996	NULL
;	NULL
149	NULL
:	NULL
2023-20035.	NULL
.	NULL

Koken	NULL
MHM	NULL
Linares	NULL
Cruz	NULL
G	NULL
,	NULL
Quignon	NULL
E	NULL
et	NULL
L	NULL
The	NULL
PML	NULL
grow	NULL
th	NULL
suppressor	NULL
has	NULL
an	NULL
altered	NULL
expression	NULL
in	NULL
human	NULL
oncogenesis	NULL
.	NULL

Oncogene	NULL
1995	NULL
;	NULL
10	NULL
:	NULL
1315-1324	NULL
.	NULL

Sen	NULL
GC	NULL
,	NULL
Lengyel	NULL
B	NULL
The	NULL
interferon	NULL
system	NULL
.	NULL

J	NULL
BioZ/	NULL
Chem	NULL
1992	NULL
;	NULL
267	NULL
:	NULL
5017-5020	NULL
.	NULL

Fischer	NULL
Wiegmann	NULL
K	NULL
,	NULL
Bottinger	NULL
H	NULL
,	NULL
Morens	NULL
K	NULL
,	NULL
Burmester	NULL
G	NULL
,	NULL
Pfizenmaier	NULL
K.	NULL
Regulation	NULL
of	NULL
IFN-y-receptor	NULL
expression	NULL
in	NULL
human	NULL
monocytes	NULL
by	NULL
granulocyte-macrophage	NULL
colony-stimulating	NULL
factor	NULL
.	NULL

J	NULL
Immunol	NULL
1990	NULL
;	NULL
145	NULL
:	NULL
2914-2919	NULL
.	NULL

Chomczynski	NULL
B	NULL
Sacchi	NULL
N.	NULL
Single	NULL
step	NULL
method	NULL
of	NULL
RNA	NULL
isolation	NULL
by	NULL
guanidinium	NULL
thiocyanatephenol-chloroform	NULL
extraction	NULL
.	NULL

Anal	NULL
Biochem	NULL
1987	NULL
;	NULL
162	NULL
:	NULL
156-159	NULL
.	NULL

13	NULL
.	NULL

14	NULL
.	NULL

15	NULL
.	NULL

16	NULL
.	NULL

17	NULL
.	NULL

18	NULL
.	NULL

19	NULL
.	NULL

20	NULL
.	NULL

21	NULL
.	NULL

22	NULL
.	NULL

Goddard	NULL
AD	NULL
,	NULL
Borrow	NULL
J	NULL
,	NULL
Freemont	NULL
PS	NULL
,	NULL
Solomon	NULL
E.	NULL
Characterization	NULL
of	NULL
a	NULL
zinc	NULL
finger	NULL
gene	NULL
disrupted	NULL
by	NULL
the	NULL
i	NULL
(	NULL
15	NULL
;	NULL
17	NULL
)	NULL
in	NULL
acute	NULL
promyelocytic	NULL
leukemia	NULL
.	NULL

Science	NULL
1991	NULL
;	NULL
254	NULL
:	NULL
1371-1374	NULL
.	NULL

Flenghi	NULL
L	NULL
,	NULL
Fagioli	NULL
M	NULL
,	NULL
Tomassoni	NULL
L	NULL
,	NULL
et	NULL
44	NULL
Characterization	NULL
of	NULL
a	NULL
new	NULL
monoclonal	NULL
antibody	NULL
(	NULL
PGM3	NULL
)	NULL
directed	NULL
against	NULL
the	NULL
aminoterminal	NULL
portion	NULL
of	NULL
the	NULL
PML	NULL
gene	NULL
product	NULL
:	NULL
immunocytochemical	NULL
evidence	NULL
for	NULL
high	NULL
expression	NULL
of	NULL
PML	NULL
proteins	NULL
on	NULL
activated	NULL
macrophages	NULL
,	NULL
endothelial	NULL
cells	NULL
,	NULL
and	NULL
epithelia	NULL
.	NULL

Blood	NULL
1995	NULL
;	NULL
7	NULL
:	NULL
1871-1880	NULL
.	NULL

Chelbi-Alix	NULL
MK	NULL
,	NULL
Pelicano	NULL
L	NULL
,	NULL
Quignon	NULL
E	NULL
et	NULL
#	NULL
7	NULL
Induction	NULL
of	NULL
the	NULL
PML	NULL
protein	NULL
by	NULL
interferons	NULL
in	NULL
normal	NULL
and	NULL
APL	NULL
cells	NULL
.	NULL

Lezkem	NULL
ia	NULL
1995	NULL
;	NULL
9	NULL
:	NULL
2027-2033	NULL
.	NULL

Lavau	NULL
C	NULL
,	NULL
Marchio	NULL
A	NULL
,	NULL
Fagioli	NULL
M	NULL
,	NULL
et	NULL
al	NULL
.	NULL

The	NULL
acute	NULL
promyelocytic	NULL
lenukemia-associated	NULL
PML	NULL
gene	NULL
is	NULL
induced	NULL
by	NULL
interferon	NULL
.	NULL

Oncogene	NULL
1995	NULL
;	NULL
11	NULL
:	NULL
871-876	NULL
.	NULL

David	NULL
M	NULL
,	NULL
Romero	NULL
G	NULL
,	NULL
Zhang	NULL
ZY	NULL
,	NULL
Dixon	NULL
JE	NULL
,	NULL
Larner	NULL
AC	NULL
.	NULL

In	NULL
vitro	NULL
activation	NULL
of	NULL
the	NULL
transcription	NULL
factor	NULL
ISGF3	NULL
by	NULL
interferon	NULL
involves	NULL
a	NULL
membrane-associated	NULL
tyrosine	NULL
phosphatase	NULL
and	NULL
tyrosine	NULL
kinase	NULL
.	NULL

/	NULL
Bio/	NULL
Chem	NULL
1993	NULL
;	NULL
268	NULL
:	NULL
6593-6599	NULL
.	NULL

Stadler	NULL
M	NULL
,	NULL
Chelbi-Alix	NULL
MK	NULL
,	NULL
Koken	NULL
MHM	NULL
,	NULL
e	NULL
?	NULL

42	NULL
Transcriptional	NULL
induction	NULL
of	NULL
the	NULL
PML	NULL
grow	NULL
th	NULL
suppressor	NULL
gene	NULL
by	NULL
interferons	NULL
is	NULL
mediated	NULL
through	NULL
an	NULL
ISRE	NULL
and	NULL
a	NULL
GAS	NULL
element	NULL
.	NULL

Oncogene	NULL
1995	NULL
;	NULL
11	NULL
:	NULL
2565-2573	NULL
.	NULL

Ransohoff	NULL
RM	NULL
.	NULL

Cellular	NULL
responses	NULL
to	NULL
interferons	NULL
and	NULL
other	NULL
cytokines	NULL
:	NULL
the	NULL
JAK-STAT	NULL
paradigm	NULL
.	NULL

N	NULL
Engl	NULL
J	NULL
Med	NULL
1998	NULL
;	NULL
338	NULL
:	NULL
616-618	NULL
.	NULL

Visa	NULL
N	NULL
,	NULL
et	NULL
4L	NULL
Intranuclear	NULL
distribution	NULL
of	NULL
poly	NULL
A	NULL
RNA	NULL
determined	NULL
by	NULL
electron	NULL
microscopy	NULL
in	NULL
situ	NULL
hybridization	NULL
.	NULL

Exp	NULL
Cell	NULL
Res	NULL
1993	NULL
;	NULL
208	NULL
:	NULL
19-34	NULL
.	NULL

Balkw	NULL
ill	NULL
FR	NULL
.	NULL

The	NULL
other	NULL
interleukins	NULL
.	NULL

In	NULL
:	NULL
Balkwill	NULL
FR	NULL
.	NULL

Cytokines	NULL
in	NULL
Cencer	NULL
Therapy	NULL
.	NULL

Oxford	NULL
:	NULL
Oxford	NULL
University	NULL
Press	NULL
,	NULL
1989	NULL
;	NULL
150-182	NULL
.	NULL

Dinarello	NULL
CA	NULL
.	NULL

Biologic	NULL
basis	NULL
for	NULL
interleukin	NULL
]	NULL
in	NULL
disease	NULL
.	NULL

Blood	NULL
1996	NULL
;	NULL
87	NULL
:	NULL
2095-2147	NULL
ACKNOWLEDGEMENTS	NULL
.	NULL

This	NULL
work	NULL
was	NULL
supported	NULL
by	NULL
Grant	NULL
405/1-4	NULL
from	NULL
the	NULL
German	NULL
Research	NULL
Council	NULL
(	NULL
Deutsche	NULL
Forschungsgemeinschafi	NULL
)	NULL
.	NULL

This	NULL
work	NULL
is	NULL
in	NULL
partial	NULL
fulfilment	NULL
of	NULL
MH	NULL
's	NULL
'Medical	NULL
Thesis	NULL
'	NULL
.	NULL

Received	NULL
8	NULL
June	NULL
1998	NULL
;	NULL
accepted	NULL
in	NULL
revised	NULL
form	NULL
23	NULL
July	NULL
1998	NULL
Mediators	NULL
of	NULL
Inflammation	NULL
-	NULL
Vol	NULL
7	NULL
-	NULL
1998	NULL
325	NULL

